177 related articles for article (PubMed ID: 31471324)
21. Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma.
Meehan KR; Wu J; Bengtson E; Hill J; Ely P; Szczepiorkowski Z; Kendall M; Ernstoff MS
Bone Marrow Transplant; 2007 Jun; 39(11):695-703. PubMed ID: 17417660
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells.
Kim N; Jeon YW; Nam YS; Lim JY; Im KI; Lee ES; Cho SG
Cytokine; 2016 Feb; 78():22-6. PubMed ID: 26624506
[TBL] [Abstract][Full Text] [Related]
23. Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
DeFilipp Z; Li S; Kempner ME; Brown J; Del Rio C; Valles B; Hunnewell C; Saylor M; Vanderklish J; Dey BR; El-Jawahri A; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1836-1840. PubMed ID: 29758393
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
25. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.
Xie Y; Wu M; Song R; Ma J; Shi Y; Qin W; Jin Y
Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):781-91. PubMed ID: 19727527
[TBL] [Abstract][Full Text] [Related]
26. Potential limitations of IL-2 administration for the treatment of experimental acute graft-versus-host disease.
Pérol L; Martin GH; Maury S; Cohen JL; Piaggio E
Immunol Lett; 2014 Dec; 162(2 Pt B):173-84. PubMed ID: 25445496
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.
Heiler S; Lötscher J; Kreuzaler M; Rolink J; Rolink A
Front Immunol; 2018; 9():656. PubMed ID: 29670626
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
Koshy AG; Kim HT; Liegel J; Arnason J; Ho VT; Antin JH; Joyce R; Cutler C; Gooptu M; Nikiforow S; Logan EK; Elavalakanar P; Narcis M; Stroopinsky D; Avigan ZM; Boussi L; Stephenson S; El Banna H; Bindal P; Cheloni G; Avigan DE; Soiffer RJ; Rosenblatt J
Blood; 2023 Jun; 141(24):2932-2943. PubMed ID: 36862975
[TBL] [Abstract][Full Text] [Related]
29. [Effect of Low-Dose Recombinant Interleukin-2 Therapy on Immunocyte Subsets in Children with Solid Tumor].
Lei JY; Li Y; Li CM; Xiong XL; Feng CC; Weng WJ; Peng XM; Zhou DH; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):445-449. PubMed ID: 38660850
[TBL] [Abstract][Full Text] [Related]
30. A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease.
Salhotra A; Falk L; Park G; Sandhu K; Ali H; Modi B; Hui S; Nakamura R
Expert Rev Clin Immunol; 2024 Feb; 20(2):169-184. PubMed ID: 37921226
[TBL] [Abstract][Full Text] [Related]
31. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
Akpek G; Lee SM; Anders V; Vogelsang GB
Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
[TBL] [Abstract][Full Text] [Related]
32. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study.
Greinix HT; van Besien K; Elmaagacli AH; Hillen U; Grigg A; Knobler R; Parenti D; Reddy V; Theunissen K; Michallet M; Flowers ME;
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1775-82. PubMed ID: 21621629
[TBL] [Abstract][Full Text] [Related]
33. CD4(+) and CD8(+) regulatory T cells in chronic rhinosinusitis mucosa.
Pant H; Hughes A; Schembri M; Miljkovic D; Krumbiegel D
Am J Rhinol Allergy; 2014; 28(2):e83-9. PubMed ID: 24717938
[TBL] [Abstract][Full Text] [Related]
34. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
[TBL] [Abstract][Full Text] [Related]
35. Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients.
Velilla PA; Shata MT; Lages CS; Ying J; Fichtenbaum CJ; Chougnet C
AIDS Res Hum Retroviruses; 2008 Jan; 24(1):52-61. PubMed ID: 18275348
[TBL] [Abstract][Full Text] [Related]
36. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
37. Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.
Fransolet G; Ehx G; Somja J; Delens L; Hannon M; Muller J; Dubois S; Drion P; Caers J; Humblet-Baron S; Delvenne P; Beguin Y; Conteduca G; Baron F
J Hematol Oncol; 2016 Jul; 9(1):53. PubMed ID: 27377819
[TBL] [Abstract][Full Text] [Related]
38. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.
Yamashita K; Horwitz ME; Kwatemaa A; Nomicos E; Castro K; Sokolic R; Foster SF; Garofalo M; Choi U; Ryherd M; Brown MR; Leitman SF; Wayne AS; Fowler DH; Bishop MR; Childs RW; Barrett AJ; Pavletic SZ; Malech HL
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):22-30. PubMed ID: 16399598
[TBL] [Abstract][Full Text] [Related]
39. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.
van Tilburg CM; Milde T; Witt R; Ecker J; Hielscher T; Seitz A; Schenk JP; Buhl JL; Riehl D; Frühwald MC; Pekrun A; Rossig C; Wieland R; Flotho C; Kordes U; Gruhn B; Simon T; Linderkamp C; Sahm F; Taylor L; Freitag A; Burhenne J; Foerster KI; Meid AD; Pfister SM; Karapanagiotou-Schenkel I; Witt O
Clin Epigenetics; 2019 Dec; 11(1):188. PubMed ID: 31823832
[TBL] [Abstract][Full Text] [Related]
40. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
